Artificial Insemination Market Size, Share, and COVID-19 Impact Analysis By Type (Intracervical Insemination, Intrauterine Insemination, Intrauterine Tuboperitoneal Insemination, and Intratubal Insemination), By Source (Husband/Partner and Donor), By End-user (Hospitals, Fertility Centers, and Others), and Regional Forecast, 2024-2032

Artificial insemination is a treatment for fertility in which sperm is delivered into a female's reproductive tract with the help of a syringe or catheter-like medical device. The source of the sperm can be the husband/partner or a known and anonymous donor. In recent years, artificial insemination has been the most common fertility treatment, and it is considered the first treatment by medical providers.

Furthermore, these treatments can be performed at home or a doctor's office. At-home artificial insemination (AI) is performed by the intravaginal insemination approach and involves delivering sperm into the vagina close to the cervix as possible. In contrast, at the doctor's office, AI is performed by intrauterine insemination with medication protocols, bloodwork, and ultrasound monitoring to track egg development.

The increasing prevalence of male infertility has fueled the demand for artificial insemination treatment. For instance, as per the article published by Elsevier in December 2020, infertility affects between 8% to 12% of couples across the world, with a male factor being a contributing or primary cause in approximately 50% of couples.

Moreover, the increasing prevalence of impaired spermatogenesis has increased the demand for treatment.

Impact of COVID-19 on the Artificial Insemination Market

Due to the COVID-19 outbreak, the number of artificial insemination procedures being conducted experienced a decline in the market. The market experienced a decline as the non-essential medical services were postponed and lockdown restrictions were imposed to control the spread of the virus.

• For instance, according to the study published by Lippincott Journals in 2020, ART centers were closed in 82.5% of countries or offered limited access for special circumstances from the period of March to May 2020.

However, in 2021, the relaxation of COVID-19 restrictions by the government led to an increasing patient volume in fertility clinics, which has increased the procedures in the market.

Key Insights

The report will cover the following key insights:

• Prevalence of Infertility, by Gender, by Key Countries/Regions, 2021/2022.


• Overview: Regulatory Scenario.


• Number of Registered Fertility Clinics, Key Countries, 2022.


• Key Industry Developments (Mergers, Acquisitions, Collaborations, etc.).


• Impact of COVID-19 on the Market.

Analysis By Type

On the basis of type, intrauterine insemination is expected to grow at a substantial CAGR. Factors such as less expensive, less stress on the body, high chances of successful implantations, and low chances of infection have been fueling the segment's growth during the forecast period. Moreover, Intracervical Inseminationare expected to grow at a significant CAGR. The increasing prevalence of male infertility and easiness of performing at home has been fueling the growth of the segments.

Regional Analysis

North America accounts for a significant share of the global artificial insemination market. The primary factor responsible for North America’s largest share in the market is the increasing cases of male infertility and the growing number of infertility services.  

• For instance, according to the study published by NCBI in March 2023, the estimated male infertility rate was between 4.5-6.0% in North America.

Moreover, Asia Pacific is expected to grow at the highest CAGR due to rising awareness about artificial insemination in the region and the introduction of new fertility clinics.

Key Players Covered

The report will include the profiles of key players such as Rocket Medical plc., INVO Bioscience, Vitrolife, Pride Angel, MEDGYN PRODUCTS, INC., FUJIFILM Irvine Scientific. and others.

Segmentation

Key Industry Developments

• May 2021: The 10th Congress of Asia Pacific Initiative on Reproduction (ASPIRE) was held virtually to provide insights related to developments and future possibilities in assisted reproductive technology including artificial intelligence.


• February 2020: the Union Cabinet of India approved Assistive Reproductive Technology Regulation Bill 2020 to regulate and supervise clinics providing safe and ethical ART services to infertile couples.